Autophagy regulates anti-angiogenic property of lenvatinib in thyroid cancer.
Lingbin Xue, Zhongqin Gong, Alexander C. Vlantis, J. Y. H. Chan, Katie Meehan, C. Andrew van Hasselt, Dongcai Li, Xianhai Zeng, Minghui Wei, Michael C. F. Tong, George G. Chen
Abstract
. In conclusion, lenvatinib inhibited cell viability and induced apoptosis and autophagy in human PTC cells. Significantly, the combination of lenvatinib and autophagy inhibition may represent a novel and effective treatment option for PTC, which may be able to overcome drug resistance.
Topics & Concepts
LenvatinibAutophagyPI3K/AKT/mTOR pathwayCancer researchAngiogenesisProtein kinase BMAPK/ERK pathwayViability assayThyroid cancerApoptosisCell growthChemistryMedicinePharmacologySignal transductionCancerInternal medicineBiochemistryAutophagy in Disease and TherapyCancer, Hypoxia, and MetabolismCancer-related Molecular Pathways